Ophthalmic Solution of Smart Supramolecular Peptides to Capture Semaphorin 4D against Diabetic Retinopathy. Issue 3 (27th November 2022)

• Record Type: Journal Article
• Authors: Li, Ya‐Nan; Liang, Hong‐Wen; Zhang, Chun‐Lin; Qiu, Yan‐Mei; Wang, David; Wang, Hai‐Ling; Chen, An‐Qi; Hong, Can‐Dong; Wang, Lei; Wang, Hao; Hu, Bo
• Is Part Of: Advanced science. Volume 10:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-27
• Subjects: diabetic retinopathy -- eye drop -- semaphorin 4D -- smart supramolecular peptide; Science -- Periodicals; 505
• DOI: 10.1002/advs.202203351
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Diabetic retinopathy (DR) is the leading cause of vision loss in working age population. Intravitreal injection of anti‐VEGF antibody is widely used in clinical practice. However, about 27% of patients show poor response to anti‐VEGF therapy and about 50% of these patients continue to have macular thickening. Frequent intravitreal injections of antibody may increase the chance of endophthalmitis and cause visual loss or even blindness once happened. Therefore, there is a greatly urgent need for novel noninvasive target to treat DR clinically. Here, the formulation of a smart supramolecular peptide (SSP) eye drop for DR treatment that is effective via specifically identifying and capturing soluble semaphorin 4D (sSema4D), a strongly pro‐angiogenesis and exudates factor, is reported. The SSP nanostructures encapsulate sSema4D so that all biological effects mediated by three receptors of sSema4D are inhibited, thereby significantly alleviating pathological retinal angiogenesis and exudates in DR. Moreover, it is found that combination of SSPs eye drop and anti‐VEGF injection shows better therapeutic effect over anti‐VEGF treatment alone. Overall, SSP eye drop provide an alternative and effective method for noninvasive treatment for DR. Abstract : Diabetic retinopathy is the leading cause of vision loss in working age population. Here, the formulation of a smart supramolecular peptide (SSP) eye drop that can significantly decrease pathological retinal neovascularization and vascular leakage is reported. More importantly, it is found that combination of SSP eye drop and anti‐VEGF injection shows ≈1.5 times better therapeutic effect over anti‐VEGF treatment alone.